Clinical trials: Peripheral Blood Mononuclear Cell
- Condition Peripheral Blood Mononuclear Cell
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Leukapheresis
Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
The purpose of this protocol is to characterize the performance of CaridianBCT's Spectra Optia Apheresis System, when used to collect mononuclear cells (MNCs) and cluster of differentiation 34 (CD34) positive cells from healthy…
- Trial name
- NCT01277549
- Testing
- Mononuclear cell collection.
- Where
- 3 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Terumo BCT
Multiple Myeloma
Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure
The purpose of this investigation is to establish that hematopoetic stem cells collected on a new centrifugal blood separator, CaridianBCT's Spectra Optia Apheresis System, are able to reconstitute the hematopoetic systems of…
- Trial name
- NCT01292486
- Testing
- Spectra Optia Apheresis System
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Terumo BCT
Spondylitis, Ankylosing
Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment (Study P04465)(COMPLETED)
This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population…
- Trial name
- NCT00778869
- Testing
- Remicade
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with rheumatoid arthritis and high A3AR expression at baseline will relieve signs and symptoms of the disease.
- Trial name
- NCT01034306
- Testing
- CF101
- Where
- 5 sites in Bulgaria, Israel
- Volunteers
- 79 people
- Sponsor
- Can-Fite BioPharma